Related Experiment Video
Updated: Feb 7, 2026

Experimental Generation of Carcinoma-Associated Fibroblasts CAFs from Human Mammary Fibroblasts
Published on: October 25, 2011
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
Young Saing Kim1, Kyung Kim2, Ghee-Young Kwon3
1Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.
Background:
Recent studies suggest that FGFR3 is a potential therapeutic target in urothelial carcinoma (UC). The purpose of this study was to evaluate the rates and types of FGFR3 aberrations in patients with muscle-invasive UC who received radical resection.
Methods:
We analyzed surgical tumor samples from 74 UC patients who had received radical cystectomy (n = 40) or ureteronephrectomy (n = 34). Ion AmpliSeq Cancer Hotspot Panel v2 and nCounter Copy Number Variation Assay were used to detect FGFR3 aberrations.
Results:
Fifty-four patients (73%) had high-grade tumors, and 62% had lymph node involvement. Sixteen patients (22%) harbored FGFR3 alterations, the most common of which was FGFR3 mutations (n = 13): Y373C (n = 3), N532D (n = 3), R248C (n = 2), S249C (n = 1), G370C (n = 1), S657S (n = 1), A797P (n = 1), and 746_747insG (n = 1). Three additional patients had a FGFR3-TACC3 rearrangement. The frequency of FGFR3 aberrations was higher in bladder UC (25%) than in UC of the renal pelvis and ureter (18%) but the difference was not statistically significant (P = 0.444). Genes that were co-aberrant with FGFR3 included APC (88%), PDGFRA (81%), RET (69%), and TP53 (69%).
Conclusions:
We report the frequency and types of FGFR3 aberrations in Korean patients with UC. Patients with FGFR3 mutations or FGFR3-TACC3 fusion may constitute potential candidates for a novel FGFR-targeted therapy in the perioperative setting.
Insights
FGFR3 aberrations were found in 22% of muscle-invasive urothelial carcinoma (UC) patients. FGFR3 mutations and FGFR3-TACC3 fusions identify potential candidates for novel FGFR-targeted therapies.
Area of Science:
- Oncology
- Genetics
- Urology
Background:
- Fibroblast Growth Factor Receptor 3 (FGFR3) is implicated as a therapeutic target in urothelial carcinoma (UC).
- Understanding FGFR3 aberration profiles is crucial for developing targeted treatments in UC.
Purpose of the Study:
- To determine the frequency and types of FGFR3 aberrations in patients with muscle-invasive UC.
- To assess FGFR3 aberration rates in relation to tumor location (bladder vs. renal pelvis/ureter).
Main Methods:
- Analysis of surgical tumor samples from 74 patients undergoing radical cystectomy or ureteronephrectomy.
- Detection of FGFR3 aberrations using Ion AmpliSeq Cancer Hotspot Panel v2 and nCounter Copy Number Variation Assay.
Main Results:
- FGFR3 alterations were identified in 22% of patients, with mutations being the most common.
- Specific mutations (e.g., Y373C, N532D) and FGFR3-TACC3 rearrangements were observed.
- Higher, though not statistically significant, FGFR3 aberration rates were noted in bladder UC compared to UC of the renal pelvis and ureter.
Conclusions:
- FGFR3 aberrations are present in a significant subset of muscle-invasive UC.
- Patients with FGFR3 mutations or FGFR3-TACC3 fusions are potential candidates for perioperative FGFR-targeted therapy.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Population Growth